Atara Biotherapeutics Framtida tillväxt

Future kriterier kontrolleras 5/6

Atara Biotherapeutics förväntas öka vinsten och intäkterna med 51.1% och 32.7% per år respektive medan EPS förväntas växa med 51.5% per år.

Viktig information

51.1%

Tillväxttakt i vinsten

51.54%

Tillväxttakt för EPS

Biotechs vinsttillväxt	25.3%
Intäkternas tillväxttakt	32.7%
Framtida avkastning på eget kapital	n/a
Bevakning av analytiker	Low
Senast uppdaterad	18 May 2026

Senaste uppdateringarna om framtida tillväxt

Recent updates

Analysartikel • Feb 16

There's No Escaping Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Muted Revenues

Atara Biotherapeutics, Inc.'s ( NASDAQ:ATRA ) price-to-sales (or "P/S") ratio of 0.2x might make it look like a strong...

Seeking Alpha • Nov 30

Atara Biotherapeutics: An Empty Pipeline With Little Gas

Summary Atara Biotherapeutics is on the precipice of being behind an FDA approval for a novel cell therapy. However, they do not hold the rights for this cell therapy's commercialization. Furthermore, ATRA has suspended development of their pipeline, meaning there are few, if any, catalysts to justify buying in. Read the full article on Seeking Alpha

Analysartikel • Oct 09

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock Catapults 30% Though Its Price And Business Still Lag The Industry

Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) shares have continued their recent momentum with a 30% gain in the last...

Analysartikel • Aug 13

There's No Escaping Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Muted Revenues Despite A 25% Share Price Rise

Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) shares have continued their recent momentum with a 25% gain in the last...

Analysartikel • May 06

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Shares Fly 30% But Investors Aren't Buying For Growth

Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) shareholders are no doubt pleased to see that the share price has bounced...

Analysartikel • May 01

Is Atara Biotherapeutics (NASDAQ:ATRA) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Analysartikel • Mar 07

Lacklustre Performance Is Driving Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) 27% Price Drop

Unfortunately for some shareholders, the Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) share price has dived 27% in the...

Seeking Alpha • Jan 21

Atara Biotherapeutics: Another Dip Buying Opportunity Following CRL For CMC Issues

Summary Atara has just announced a CRL by FDA for EBVALLO. EBVALLO is already approved in Europe since December 2022 and the cause of the CRL seems minor and easily addressable. The CRL has a major impact on cash runway, considering delay in milestone payments related to approval as well as future royalties. Nevertheless, ATRA remains eligible for these future payments. This forced ATRA to suspend its CAR-T pipeline in search for strategic alternatives. On the bright side, this creates another short-term catalyst and allows ATRA to focus resources on EBVALLO. ATRA estimates that available cash along a newly announced $15M equity line of credit are sufficient to fund operations through approval, but the risk of further cash raise is real. Read the full article on Seeking Alpha

Analysartikel • Jan 16

Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Boosted 25% But Its Business Prospects Need A Lift Too

Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) shares have continued their recent momentum with a 25% gain in the last...

Analysartikel • Jan 07

Is Atara Biotherapeutics (NASDAQ:ATRA) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analysartikel • Nov 06

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement

Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) shareholders have had their patience rewarded with a 34% share price jump...

Analysartikel • Sep 06

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement

Those holding Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) shares would be relieved that the share price has rebounded...

Analysartikel • Jul 21

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock Catapults 34% Though Its Price And Business Still Lag The Industry

Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) shareholders are no doubt pleased to see that the share price has bounced...

Seeking Alpha • Jul 03

Atara Biotherapeutics: An Underestimated Contender In Autoimmune Diseases CAR-T Cell Therapy

Summary Atara Biotherapeutics is a biotech company developing allogeneic EBV T cells for oncology and autoimmune indications, with a world-first allogeneic CAR-T approval in Europe and nearing FDA approval. Assuming no regulatory delays ATRA is well-funded to deliver proof-of-concept clinical data for its CAR-T platform in both B-cell malignancies and lupus, with an estimated cash runway into 2027. Despite fierce competition, ATRA's differentiated CAR-T platform combines all the best attributes of the competition, thus having a best-in-class potential. The major short-term risk is regulatory delays, meaning delays in pending regulatory milestone payments, which would likely necessitate a cash raise. Read the full article on Seeking Alpha

Analysartikel • May 14

New Forecasts: Here's What Analysts Think The Future Holds For Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

Shareholders in Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) may be thrilled to learn that the analysts have just...

Analysartikel • May 11

Revenues Working Against Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Following 26% Dive

To the annoyance of some shareholders, Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) shares are down a considerable 26...

Seeking Alpha • Feb 06

Atara Biotherapeutics: Opportunity As They Sell Off Their Approved Asset For Longer Runway

Summary Atara Biotherapeutics is a biotech company focused on developing cell therapies for Epstein-Barr virus infection and cancer. Their most advanced product, tab-cel, has shown promising results in treating EBV-associated post-transplant lymphoproliferative disease. The company's financial situation is uncertain, but recent partnerships and potential revenue growth from tab-cel could improve their cash runway. Read the full article on Seeking Alpha

Prognoser för vinst- och omsättningstillväxt

NasdaqGS:ATRA - Analytikernas framtida uppskattningar och tidigare finansiella data (USD Millions )
Datum	Intäkter	Intäkter	Fritt kassaflöde	Kassaflöde från rörelsen	Genomsnittligt Antal analytiker
12/31/2028	42	9	N/A	4	4
12/31/2027	51	21	N/A	16	4
12/31/2026	1	-16	N/A	-12	2
3/31/2026	23	-9	-26	-26	N/A
12/31/2025	121	33	-51	-51	N/A
9/30/2025	152	23	-70	-70	N/A
6/30/2025	189	6	-64	-64	N/A
3/31/2025	200	-16	-67	-67	N/A
12/31/2024	129	-85	-69	-69	N/A
9/30/2024	100	-133	-95	-95	N/A
6/30/2024	62	-181	-142	-142	N/A
3/31/2024	35	-233	-185	-184	N/A
12/31/2023	9	-276	-194	-193	N/A
9/30/2023	5	-290	-201	-199	N/A
6/30/2023	7	-305	-214	-213	N/A
3/31/2023	57	-215	-226	-224	N/A
12/31/2022	64	-228	-275	-270	N/A
9/30/2022	71	-247	-254	-248	N/A
6/30/2022	72	-248	-252	-242	N/A
3/31/2022	24	-350	-250	-239	N/A
12/31/2021	20	-340	-231	-221	N/A
9/30/2021	13	-328	-199	-190	N/A
6/30/2021	7	-318	-190	-184	N/A
3/31/2021	4	-311	-185	-179	N/A
12/31/2020	N/A	-307	-185	-181	N/A
9/30/2020	N/A	-304	-242	-235	N/A
6/30/2020	N/A	-301	-242	-235	N/A
3/31/2020	N/A	-298	-239	-232	N/A
12/31/2019	N/A	-291	N/A	-236	N/A
9/30/2019	N/A	-292	N/A	-234	N/A
6/30/2019	N/A	-279	N/A	-230	N/A
3/31/2019	N/A	-256	N/A	-215	N/A
12/31/2018	N/A	-231	N/A	-180	N/A
9/30/2018	N/A	-186	N/A	-147	N/A
6/30/2018	N/A	-159	N/A	-119	N/A
3/31/2018	N/A	-135	N/A	-100	N/A
12/31/2017	N/A	-119	N/A	-88	N/A
9/30/2017	N/A	-102	N/A	-84	N/A
6/30/2017	N/A	-97	N/A	-79	N/A
3/31/2017	N/A	-88	N/A	-70	N/A
12/31/2016	N/A	-79	N/A	-60	N/A
9/30/2016	N/A	-82	N/A	-50	N/A
6/30/2016	N/A	-69	N/A	-48	N/A
3/31/2016	N/A	-65	N/A	-43	N/A
12/31/2015	N/A	-57	N/A	-37	N/A
9/30/2015	N/A	-46	N/A	-31	N/A

Analytiker Framtid Tillväxt Prognoser

Intäkter kontra sparande: ATRA förväntas bli lönsam under de kommande 3 åren, vilket anses vara snabbare än sparkvoten ( 3.5% ).

Resultat vs marknad: ATRA förväntas bli lönsam under de kommande 3 åren, vilket anses överstiga genomsnittet på marknaden.

Höga tillväxtresultat: ATRA förväntas bli lönsam under de kommande 3 åren.

Intäkt vs marknad: ATRA s intäkter ( 32.7% per år) förväntas växa snabbare än US marknaden ( 11.7% per år).

Hög tillväxtintäkter: ATRA s intäkter ( 32.7% per år) förutspås växa snabbare än 20% per år.

Tillväxtprognoser för vinst per aktie

Framtida avkastning på eget kapital

Framtida ROE: Otillräcklig data för att avgöra om ATRA s avkastning på eget kapital förväntas bli hög om tre år

Upptäck tillväxtföretag

Företagsanalys och finansiella data Status

Uppgifter	Senast uppdaterad (UTC-tid)
Analys av företag	2026/05/22 11:28
Aktiekurs vid dagens slut	2026/05/22 00:00
Intäkter	2026/03/31
Årlig intjäning	2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

Paket	Uppgifter	Tidsram	Exempel US-källa
Företagets finansiella ställning	10 år	Resultaträkning Kassaflödesanalys Balansräkning	SEC Form 10-K SEC Form 10-Q
Analytikernas konsensusuppskattningar	+3 år	Prognos för finansiella poster Analytikernas prismål	Rapporter från analytiker Blue Matrix
Marknadspriser	30 år	Aktiekurser Utdelningar, splittar och åtgärder	ICE Marknadsdata SEC Form S-1
Ägarskap	10 år	Största aktieägare Insiderhandel	SEC Formulär 4 SEC Formulär 13D
Förvaltning	10 år	Ledningsgrupp Styrelse och verkställande direktörer	SEC Form 10-K SEC Form DEF 14A
Viktiga utvecklingstendenser	10 år	Företagsmeddelanden	SEC Formulär 8-K

^* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Atara Biotherapeutics, Inc. bevakas av 16 analytiker. 4 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

Analytiker	Institution
John Newman	Canaccord Genuity
Yigal Nochomovitz	Citigroup Inc
Michael King	Citizens JMP Securities, LLC

Atara Biotherapeutics Framtida tillväxt

Future kriterier kontrolleras 5/6

Viktig information

Senaste uppdateringarna om framtida tillväxt

Consensus EPS estimates increase by 15%

Price target decreased by 32% to US$8.67

Consensus EPS estimates increase by 71%

Price target increased by 11% to US$17.00

Forecast to breakeven in 2025

Price target increased by 16% to US$15.33

Recent updates

President notifies of intention to sell stock

New major risk - Financial position

First quarter 2026 earnings: EPS and revenues miss analyst expectations

Atara Biotherapeutics Provides Update on Tabelecleucel Regulatory Pathway

Atara Biotherapeutics, Inc. Receives Notice of Non-Compliance with Nasdaq Listing Requirements

Atara Biotherapeutics, Inc., Annual General Meeting, Jun 09, 2026

Pomerantz Law Firm Announces Filing Of Class Action Against Atara Biotherapeutics Inc. And Certain Officers

New major risk - Shareholder dilution

Full year 2025 earnings: EPS misses analyst expectations

Atara Biotherapeutics Inc Provides Regulatory Update on Tabelecleucel

Investor sentiment improves as stock rises 36%

Atara Biotherapeutics, Inc. Announces Pierre Fabre Pharmaceuticals Submits A Request to the FDA for Type A Meeting

Consensus EPS estimates increase by 15%

There's No Escaping Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Muted Revenues

Price target decreased by 32% to US$8.67

Atara Biotherapeutics Provides Regulatory and Business Update on Ebvallo™ (Tabelecleucel)

Atara Biotherapeutics: An Empty Pipeline With Little Gas

Atara Biotherapeutics, Inc. Announces Reduction in Its Workforce

Investor sentiment deteriorates as stock falls 19%

Pierre Fabre Pharmaceuticals Inc. Announces Transfer from Atara Biotherapeutics Inc. of the Biologics License Application (Bla) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock Catapults 30% Though Its Price And Business Still Lag The Industry

Investor sentiment improves as stock rises 23%

Atara Biotherapeutics Announces Changes to Its Board of Directors

Consensus EPS estimates increase by 71%

Investor sentiment improves as stock rises 19%

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

There's No Escaping Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Muted Revenues Despite A 25% Share Price Rise

Price target increased by 11% to US$17.00

Atara Biotherapeutics, Inc. Announces U.S. Fda Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-Cel®?) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

New minor risk - Share price stability

New major risk - Shareholder dilution

Pierre Fabre Pharmaceuticals Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc

Atara Biotherapeutics, Inc. Resubmits Tabelecleucel Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

New minor risk - Insider selling

Atara Biotherapeutics, Inc. Appoints James Huang and Nachi Subramanian to Board of Directors, Effective from May 14, 2025

Forecast to breakeven in 2025

Atara Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $16.004932 million.

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Shares Fly 30% But Investors Aren't Buying For Growth

Atara Biotherapeutics, Inc. Provides Regulatory Updates on EBVALLO™? (Tabelecleucel)

Is Atara Biotherapeutics (NASDAQ:ATRA) In A Good Position To Deliver On Growth Plans?

Price target increased by 16% to US$15.33

Atara Biotherapeutics, Inc., Annual General Meeting, Jun 10, 2025

Consensus revenue estimates decrease by 96%, EPS upgraded

Price target decreased by 7.5% to US$12.25

No longer forecast to breakeven

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Lacklustre Performance Is Driving Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) 27% Price Drop

Consensus EPS estimates fall by 365%

Atara Biotherapeutics, Inc. Provides Update on Clinical Programs Related to Ebvallo™? (Tabelecleucel) and ATA3219

Atara Biotherapeutics: Another Dip Buying Opportunity Following CRL For CMC Issues

New major risk - Share price stability

Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)

Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Boosted 25% But Its Business Prospects Need A Lift Too

New major risk - Shareholder dilution

Is Atara Biotherapeutics (NASDAQ:ATRA) In A Good Position To Deliver On Growth Plans?

Forecast to breakeven in 2027

New minor risk - Profitability

Consensus revenue estimates increase by 14%

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement

Atara Biotherapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Atara Biotherapeutics, Inc. Appoints Eric Hyllengren as Chief Operating Officer

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement

Atara Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $36 million.

Insufficient new directors

Consensus revenue estimates decrease by 15%, EPS upgraded

Consensus EPS estimates fall by 52%, revenue upgraded

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Atara Biotherapeutics, Inc. Announces CEO Changes, Effective September 9, 2024